Researchers are exploring ways to improve the prediction of MGMT methylation status in glioblastoma patients using various approaches, including radiomics features and machine learning. Some studies are investigating the use of MRI imaging and multi-omics analysis to predict MGMT promoter methylation, while others are examining the relationship between MGMT methylation and treatment outcomes. The effectiveness of MGMT methylation as a predictor of response to certain treatments, such as temozolomide, is also being studied, with some findings suggesting it may not be a reliable predictor in all cases.